Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Based on these results Eleven sees no immediate path forward in allergic conjunctivitis and will advance development of EBI-031 for diabetic macular edema with an IND filing in 1H2016.
